Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):223-9.
Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.
Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):230-8.
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D, Martin PJ
A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002; 8(1):32-9.
A survey of diagnosis, management, and grading of chronic GVHD.
Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P
a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379.
a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 03; 24(3):282-291.
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells. 2001; 19(2):108-17.
Peripheral blood stem cells for allogeneic transplantation: a review.
Nahas MR, Soiffer RJ, Kim HT, Alyea EP, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845.
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ
Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988 Mar; 71(3):690-6.
Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.
Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, Antin JH
Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 1987 Jan; 69(1):187-91.
Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?
Graft-versus-leukemia: no longer an epiphenomenon. Blood. 1993 Oct 15; 82(8):2273-7.
Graft-versus-leukemia: no longer an epiphenomenon.
Ibrahim RE, Teich D, Smith BR, Antin J, Olivier AP, Weinberg DS
Flow cytometric surface light chain analysis of lymphocyte-rich effusions. A useful adjunct to cytologic diagnosis. Cancer. 1989 May 15; 63(10):2024-9.
Flow cytometric surface light chain analysis of lymphocyte-rich effusions. A useful adjunct to cytologic diagnosis.
Chang G, Meadows ME, Jones JA, Antin JH, Orav EJ
The American journal of drug and alcohol abuse
Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). Am J Drug Alcohol Abuse. 2010 Jan; 36(1):1-6.
Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Apr 10; 24(4):526.
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC
Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22.
Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation.
Approaches to graft-vs-host disease. Pediatr Transplant. 2005 Dec; 9 Suppl 7:71-5.
Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009 Jun; 145(6):816-24.
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.
Koreth J, Biernacki M, Aldridge J, Kim HT, Alyea EP, Armand P, Cutler C, Ho VT, Wu CJ, Antin JH, Soiffer RJ
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8.
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
Kubiak DW, Koo S, Hammond SP, Armand P, Baden LR, Antin JH, Marty FM
Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1462-5.
Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, Kupiec-Weglinski S, Soiffer R, Ritz J, Antin JH, Alyea E, Koreth J, Cutler C, Armand P, Paik JM, Leaf DE, Ho VT, Abdi R
Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353.
Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.
Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990 Oct; 8(10):1707-14.
Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia.
Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, Lehmann L, Shore T, Ho VT, Bunin N, Iacobelli M, Liang W, Hume R, Tappe W, Soiffer R, Richardson P
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827.
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9.
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
Seeley WW, Marty FM, Holmes TM, Upchurch K, Soiffer RJ, Antin JH, Baden LR, Bromfield EB
Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007 Jul 10; 69(2):156-65.
Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6.
Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA
Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 1990 Dec 01; 76(11):2354-9.
Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy.
Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH, Soiffer RJ
Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002 Oct 15; 100(8):2697-702.
Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.
Porcheray F, Miklos DB, Floyd BH, Sarantopoulos S, Bellucci R, Soiffer RJ, Antin JH, Alyea EP, Ritz J, Zorn E
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15; 92(3):359-65.
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.
Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M, Cahn JY, Cairo MS, Herzig RH, Isola LM, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman SR, Weisdorf DJ, Wingard JR, Horowitz MM, Pavletic SZ
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011 Oct 20; 118(16):4472-9.
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec; 12(13):1195-203.
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
Interleukin-2 and regulatory T cells in graft-versus-host disease.
Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, Messinger Y, Liang W, Hume R, Tappe W, Soiffer RJ, Grupp SA
Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269.
Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Cheng MP, Pandit A, Antin JH, Walsh SR, Huynh D, Ghobrial IM, Baden LR, Marty FM, Issa NC
Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Adv. 2018 06 12; 2(11):1272-1276.
Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.
Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, Antin JH, Ritz J
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19; 199(8):1133-42.
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.
Humphreys BD, Vanguri VK, Henderson J, Antin JH
Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient. Nat Clin Pract Nephrol. 2006 Sep; 2(9):535-9; quiz 540.
Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient.
Antin JH, Ault KA, Rappeport JM, Smith BR
B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J Clin Invest. 1987 Aug; 80(2):325-32.
B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes.
ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion. 1999 Nov-Dec; 39(11-12):1273-4.
ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity.
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17.
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
Vitamin D and citrate synthesis. Arch Biochem Biophys. 1959 Apr; 81(2):340-5.
Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13.
A disease risk index for patients undergoing allogeneic stem cell transplantation.
Knoll BM, Peixoto D, Koo S, Hammond SP, Ho VT, Antin JH, Soiffer RJ, Cutler C, Marty FM
Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. Biol Blood Marrow Transplant. 2018 10; 24(10):2164-2165.
Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis.
Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, Alyea EP, Ho VT, Soiffer RJ, Antin JH, Ritz J
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83.
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, Pavletic SZ
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011 Jun 16; 117(24):6714-20.
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, Horowitz MM, Marsh JC, Deeg HJ
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011 Sep 01; 118(9):2618-21.
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.
Antin JH, Emerson SG, Martin P, Gadol N, Ault KA
Journal of immunology (Baltimore, Md. : 1950)
Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol. 1986 Jan; 136(2):505-10.
Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies.
Chang G, Orav EJ, McNamara TK, Tong MY, Antin JH
Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics. 2005 Jan-Feb; 46(1):34-40.
Psychosocial function after hematopoietic stem cell transplantation.
Schneider LC, Antin JH, Weinstein H, Abrams JS, Pearce MK, Geha RS, Vercelli D
Lymphokine profile in bone marrow transplant recipients. Blood. 1991 Dec 01; 78(11):3076-80.
Lymphokine profile in bone marrow transplant recipients.
The clinical spectrum of acute graft-versus-host disease. Semin Hematol. 2006 Jan; 43(1):24-31.
The clinical spectrum of acute graft-versus-host disease.
Haspel RL, Kao G, Yeap BY, Cutler C, Soiffer RJ, Alyea EP, Ho VT, Koreth J, Dey BR, McAfee SL, Attar EC, Spitzer T, Antin JH, Ballen KK
Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9.
Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.
Delaney M, Cutler CS, Haspel RL, Yeap BY, McAfee SL, Dey BR, Attar E, Kao G, Alyea EP, Koreth J, Ho VT, Saidman S, Liney D, Sese D, Soiffer RJ, Spitzer TR, Antin JH, Ballen KK
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002.
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
Antin JH, Aplin AE, Cheng SY, Emmert-Buck MR, Cryns VL, Wang D
American journal of cancer research: editorial board (2011). Am J Cancer Res. 2011; 1(6):817-22.
American journal of cancer research: editorial board (2011).
Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007 May; 13(5):505-16.
Allogeneic stem cell transplantation for aplastic anemia.
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15; 112(8):3500-7.
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J, Wu C, Antin JH, Soiffer RJ, Gribben JG, Alyea EP
Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9.
Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C
Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. 2018 10; 103(10):1708-1719.
Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.
Young RC, Gibbs J, Antin J, Holt J, Smith GP
Journal of comparative and physiological psychology
Absence of satiety during sham feeding in the rat. J Comp Physiol Psychol. 1974 Nov; 87(5):795-800.
Absence of satiety during sham feeding in the rat.
Holt J, Antin J, Gibbs J, Young RC, Smith GP
Cholecystokinin does not produce bait shyness in rats. Physiol Behav. 1974 Mar; 12(3):497-8.
Cholecystokinin does not produce bait shyness in rats.
Guinan EC, Molrine DC, Antin JH, Lee MC, Weinstein HJ, Sallan SE, Parsons SK, Wheeler C, Gross W, McGarigle C
Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994 Mar 15; 57(5):677-84.
Polysaccharide conjugate vaccine responses in bone marrow transplant patients.
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144.
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990 Apr; 8(4):648-56.
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, Horowitz MM, Petersdorf EW
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009 Apr 01; 27(10):1644-52.
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.
Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, Antin JH, Ritz J, Canning C, Kutok J, Mihm MC, Dranoff G, Soiffer R
Proceedings of the National Academy of Sciences of the United States of America
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30.
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31.
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
Ballen KK, Cutler C, Yeap BY, McAfee SL, Dey BR, Attar EC, Chen YB, Haspel RL, Liney D, Koreth J, Ho V, Alyea EP, Soiffer RJ, Spitzer TR, Antin JH
Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31.
Donor-derived second hematologic malignancies after cord blood transplantation.
Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60.
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
Hill JA, Koo S, Guzman Suarez BB, Ho VT, Cutler C, Koreth J, Armand P, Alyea EP, Baden LR, Antin JH, Soiffer RJ, Marty FM
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1638-48.
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85.
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Antin JH, Smith BR, Holmes W, David RN, Rosenthal S
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Inst Mitt. 1988 Aug; (83):149-53.
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Goldberg MA, Antin JH, Guinan EC, Rappeport JM
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986 Nov; 68(5):1114-8.
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C
Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019 03; 25(3):488-495.
Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.
Mitus AJ, Antin JH, Rutherford CJ, McGarigle CJ, Goldberg MA
Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. Blood. 1994 Apr 01; 83(7):1952-7.
Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs.
Carty MJ, Pribaz JJ, Antin JH, Volpicelli ER, Toomey CE, Farkash EA, Hochberg EP
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg. 2011 Sep; 128(3):112e-118e.
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast.
Marty FM, Petschnigg EM, Hammond SP, Ready JE, Ho VT, Soiffer RJ, Magee C, Milner DA, Antin JH, Baden LR
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Invasive fungal disease after remote inoculation in transplant recipients. Clin Infect Dis. 2011 Jan 01; 52(1):e7-10.
Invasive fungal disease after remote inoculation in transplant recipients.
Gazourian L, Coronata AM, Rogers AJ, Weinhouse GL, Soiffer RJ, Antin JH, Ritz J, Ho VT, Baron RM, Washko GR
Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83.
Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
Andrykowski MA, Greiner CB, Altmaier EM, Burish TG, Antin JH, Gingrich R, McGarigle C, Henslee-Downey PJ
Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer. 1995 Jun; 71(6):1322-9.
Quality of life following bone marrow transplantation: findings from a multicentre study.
Maziarz RT, Tepler I, Antin JH, Keroack MA, Churchill WH, Holmes W, Rappeport J
Reversal of infection with Mycobacterium avium intracellulare by treatment with alpha-interferon in a patient with hairy cell leukemia. Ann Intern Med. 1988 Aug 15; 109(4):292-4.
Reversal of infection with Mycobacterium avium intracellulare by treatment with alpha-interferon in a patient with hairy cell leukemia.
Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BR
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
An overview of hematopoietic stem cell transplantation. Clin Chest Med. 2005 Dec; 26(4):517-27, v.
An overview of hematopoietic stem cell transplantation.
Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci. 1994 Sep; 4(1):12-4; discussion 14-6.
Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant.
Chronic graft-versus-host disease. Curr Opin Oncol. 2006 Mar; 18(2):126-31.
Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R, Phillips GL, LeMaistre CF, Gilliland G, Antin JH, Martin P
Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990 Apr 01; 75(7):1426-32.
Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
Araten DJ, Lawton T, Ferrara J, Antin JH, Milford E, Carpenter CB, Maziarz RT
In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance. Transplantation. 1993 Jan; 55(1):76-82.
In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance.
Fay JW, Wingard JR, Antin JH, Collins RH, Piñeiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ
FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood. 1996 Apr 15; 87(8):3514-9.
FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.
Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, Herrera MI, Reynolds CG, Alyea EP, Ho VT, Koreth J, Armand P, Chen YB, Ballen K, Soiffer RJ, Antin JH, Cutler CS, Ritz J
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74.
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
Cholecystokinin interacts with pregastric food stimulation to elicit satiety in the rat. Physiol Behav. 1978 Jan; 20(1):67-70.
Cholecystokinin interacts with pregastric food stimulation to elicit satiety in the rat.
Evidence that pluripotential stem cells form splenic colonies in humans after marrow transplantation. Transplantation. 1985 Jan; 39(1):102-5.
Evidence that pluripotential stem cells form splenic colonies in humans after marrow transplantation.
Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH
Improved survival for patients with acute myelogenous leukemia. J Clin Oncol. 1995 Mar; 13(3):560-9.
Improved survival for patients with acute myelogenous leukemia.
Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, Antin JH, Bierer BE
Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood. 1994 Dec 01; 84(11):3974-9.
Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A.
Martin PJ, Antin JH, Weisdorf DJ, Paton V, Horowitz MM
Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(6):295-302.
Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation.
Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Progress in clinical and biological research
Cytokines and graft-V-host disease. Prog Clin Biol Res. 1994; 390:193-202.
Hematology/oncology clinics of North America
Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am. 1993 Apr; 7(2):477-93.
Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes.
Molrine DC, Guinan EC, Antin JH, Parsons SK, Weinstein HJ, Wheeler C, McGarigle C, Blanding P, Phillips NR, Kinsella K, Deans K, Ciamarra A, Goorin A, George S, Ambrosino DM
Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996 Apr 01; 87(7):3012-8.
Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation.
Antin JH, Ginsburg D, Smith BR, Nathan DG, Orkin SH, Rappeport JM
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985 Dec; 66(6):1247-50.
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment.
Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007 Jul 15; 110(2):490-500.
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.
Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S18-27.
Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol. 2008 Oct; 1(1):111.
Current and future approaches for control of graft-versus-host disease.
Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010 Jul 22; 116(3):366-74.
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G
Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol. 1993 May; 11(5):937-42.
Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome.
Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH
ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion. 1999 Feb; 39(2):179-87.
ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation.
Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001 Aug 15; 19(16):3685-91.
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.
Symptoms of pain and depression in related marrow donors: changes after transplant. Psychosomatics. 2003 Jan-Feb; 44(1):59-64.
Symptoms of pain and depression in related marrow donors: changes after transplant.
Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
Novel drugs for the prevention and treatment of acute GVHD. Curr Pharm Des. 2008; 14(20):1962-73.
Novel drugs for the prevention and treatment of acute GVHD.
Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ
Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7.
Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy.
Englert JA, Cho MH, Lamb AE, Shumyatcher M, Barragan-Bradford D, Basil MC, Higuera A, Isabelle C, Vera MP, Dieffenbach PB, Fredenburgh LE, Kang JB, Bhatt AS, Antin JH, Ho VT, Soiffer RJ, Howrylak JA, Himes BE, Baron RM
Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2019 Jan 21; 20(1):15.
Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation.
Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leuk Lymphoma. 1995 Apr; 17(3-4):191-7.
Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation.
Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease.
Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar; 6(3):e132-e143.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Ritz J, Soiffer RJ, Koreth J
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Whangbo JS, Kim HT, Nikiforow S, Koreth J, Alho AC, Falahee B, Kim S, Dusenbury K, Fields MJ, Reynolds CG, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994.
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Amonoo HL, Brown LA, Scheu CF, Millstein RA, Pirl WF, Vitagliano HL, Antin JH, Huffman JC
Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. Psychooncology. 2019 08; 28(8):1633-1639.
Positive psychological experiences in allogeneic hematopoietic stem cell transplantation.
Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755.
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS
Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019 11; 25(11):2143-2151.
Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen K, Marty FM, Tan CS, Ritz J, Politikos I, Boussiotis V
Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clin Immunol. 2019 10; 207:18-23.
Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells.
Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR
Clinical cancer research : an official journal of the American Association for Cancer Research
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.
Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Chen YB, Armand P, Shadman M
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019 12; 25(12):2383-2387.
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.
Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561.
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013 May-Jun; 58(3):233-51.
Ocular graft-versus-host disease: a review.
Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. JAMA Oncol. 2020 Jan 01; 6(1):e192974.
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.
Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Politikos I, Boussiotis VA
Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplant. 2020 09; 55(9):1821-1823.
Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation.
DeFilipp Z, Li S, Avigan D, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, Spitzer TR, Chen YB, Soiffer RJ, Antin JH, Ballen KK, Cutler CS
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation.
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D, Vicent MG, Hashem H, Kamble RT, Kasow KA, Lazarus HM, Mathews V, Orchard PJ, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey AE, Saldaña BD, Savani B, Winiarski J, Yared J, Weisdorf DJ, Antin JH, Eapen M
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019 10 22; 3(20):3123-3131.
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.
Thangavelu G, Du J, Paz KG, Loschi M, Zaiken MC, Flynn R, Taylor PA, Kirchmeier AK, Panoskaltsis-Mortari A, Luznik L, MacDonald KP, Hill GR, Maillard I, Munn DH, Serody JS, Murphy WJ, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Dahlberg C, Miller AT, Blazar BR
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease.
Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT
Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539.
Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020 01 09; 135(2):97-107.
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG
Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):606-611.
Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.
Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020 04; 26(4):798-804.
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
The role of regulatory T cells in graft-versus-host disease management. Expert Rev Hematol. 2020 02; 13(2):141-154.
The role of regulatory T cells in graft-versus-host disease management.
Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N
Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2020 05; 26(5):e94-e100.
Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.
Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. Ann Hematol. 2020 Apr; 99(4):743-752.
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Rev Hematol. 2020 05; 13(5):519-532.
Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape.
Fantozzi PJ, Villa A, Antin JH, Treister N
Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2020 09; 55(9):1844-1846.
Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients.
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020 06 20; 38(18):2062-2076.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
Espada E, Cheng MP, Kim HT, Woolley AE, Avigan JI, Forcade E, Soares MVD, Lacerda JF, Nikiforow S, Gooptu M, Romee R, Alyea EP, Armand P, Cutler CS, Ho VT, Koreth J, Antin JH, Soiffer RJ, Marty FM, Ritz J
BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.
Myers K, Hebert K, Antin J, Boulad F, Burroughs L, Hofmann I, Kamble R, MacMillan ML, Eapen M
Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. Biol Blood Marrow Transplant. 2020 08; 26(8):1446-1451.
Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome.
Myllymäki M, Redd RA, Reilly CR, Saber W, Spellman S, Gibson CJ, Hu ZH, Wang T, Orr EH, Grenier JG, Chen MM, Steensma DP, Cutler C, De Vivo I, Antin JH, Neuberg D, Agarwal S, Lindsley RC
Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. Blood. 2020 Aug 17.
Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome.
Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Armand P, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, Ritz J, Brown JR
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.
Fuchs EJ, O'Donnell PV, Eapen M, Logan BR, Antin JH, Dawson P, Devine SM, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG
Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood. 2020 Aug 31.
Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101).
Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C
Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217.
Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175.
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
Myllymäki M, Redd R, Reilly CR, Saber W, Spellman SR, Gibson CJ, Hu ZH, Wang T, Orr EH, Grenier JG, Chen MM, Steensma DP, Cutler C, De Vivo I, Antin JH, Neuberg D, Agarwal S, Lindsley RC
Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020 12 24; 136(26):3070-3081.
Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome.
Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021 01 21; 137(3):420-428.
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Arihara Y, Kubo T, Buon L, Gooptu M, Koreth J, Cutler C, Nikiforow S, Ho VT, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, Ritz J, Romee R
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
Maurer K, Saucier A, Kim HT, Acharya U, Mo CC, Porter J, Albert C, Cutler C, Antin JH, Koreth J, Gooptu M, Romee R, Wu CJ, Soiffer RJ, Nikiforow S, Jacobson C, Ho VT
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.
Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Chen EC, Li S, Eisfeld AK, Luskin MR, Mims A, Jones D, Antin JH, Cutler CS, Koreth J, Ho VT, Gooptu M, Romee R, El-Jawahri A, McAfee SL, DeFilipp Z, Soiffer RJ, Chen YB, Fathi AT
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7.
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
GVHD Prophylaxis 2020. Front Immunol. 2021; 12:605726.
Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Apr 13.
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis.
Luo ZK, Domenech-Estarellas EA, Han A, Lee D, Khatri R, Wahl JL, Cutler C, Armand P, Antin JH, Koreth J, Gooptu M, Alyea EP, Soiffer RJ, Ho VT
Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2021 05; 27(5):433.e1-433.e8.
Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease.
Reilly CR, Myllymäki M, Redd R, Padmanaban S, Karunakaran D, Tesmer V, Tsai FD, Gibson CJ, Rana HQ, Zhong L, Saber W, Spellman SR, Hu ZH, Orr EH, Chen MM, De Vivo I, DeAngelo DJ, Cutler C, Antin JH, Neuberg D, Garber JE, Nandakumar J, Agarwal S, Lindsley RC
The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 09 09; 138(10):898-911.
The clinical and functional effects of TERT variants in myelodysplastic syndrome.
Heeney MM, Berhe S, Campagna DR, Oved JH, Kurre P, Shaw PJ, Teo J, Shanap MA, Hassab HM, Glader BE, Shah S, Yoshimi A, Ameri A, Antin JH, Boudreaux J, Briones M, Dickerson KE, Fernandez CV, Farah R, Hasle H, Keel SB, Olson TS, Powers JM, Rose MJ, Shimamura A, Bottomley SS, Fleming MD
SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Hum Mutat. 2021 11; 42(11):1367-1383.
SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature.
Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021 07 22; 138(3):273-282.
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Antin JH, Ritz J, Soiffer RJ, Wu CJ, Brown JR
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222.
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.
Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, Jaglowski S, Pidala J, Cutler C
Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021 12; 27(12):990.e1-990.e7.
Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Garcia JS, Kim HT, Murdock HM, Cutler CS, Brock J, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, Loschi F, Ryan J, Fell G, Karp HQ, Lucas F, Kim AS, Potter D, Mashaka T, Stone RM, DeAngelo DJ, Letai A, Lindsley RC, Soiffer RJ, Antin JH
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545.
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
Maurer K, Kim HT, Kuczmarski TM, Garrity HM, Weber A, Reynolds CG, Liney D, Cutler C, Antin JH, Koreth J, Ritz J, Shapiro RM, Romee R, Wu CJ, Soiffer RJ, Nikiforow S, Ho VT, Gooptu M
Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021 12 14; 5(23):5140-5149.
Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution.
Nauffal M, Kim HT, Richardson PG, Soiffer RJ, Antin JH, Cutler C, Nikiforow S, Gooptu M, Koreth J, Romee R, Ho VT
Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Adv. 2022 01 11; 6(1):181-188.
Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2022 01 10; 40(2):189-201.
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplant Cell Ther. 2022 02; 28(2):109.e1-109.e8.
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194.
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KPA, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J, Blazar BR
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, Rambaldi B, Arihara Y, Reynolds C, Halpern MS, Rodig SJ, Cullen N, Wolff JO, Pfaff KL, Lane AA, Lindsley RC, Cutler CS, Antin JH, Ho VT, Koreth J, Gooptu M, Kim HT, Malmberg KJ, Wu CJ, Chen J, Soiffer RJ, Ritz J, Romee R
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11).
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.
Whangbo JS, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SC, Kim S, Burden A, Alho AC, Lacerda JF, Alyea EP, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J, Koreth J
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022 11 08; 6(21):5786-5796.
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Gooptu M, Kim HT, Jacobsen E, Fisher DC, LaCasce A, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, Berliner N, Nikiforow S
Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2023 06 13; 7(11):2309-2316.
Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis.
Rambaldi B, Kim HT, Arihara Y, Asano T, Reynolds C, Manter M, Halpern M, Weber A, Koreth J, Cutler C, Gooptu M, Nikiforow S, Ho VT, Antin JH, Romee R, Ampudia J, Ng C, Connelly S, Soiffer RJ, Ritz J
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica. 2022 11 01; 107(11):2617-2629.
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.
Little JS, Shapiro RM, Aleissa MM, Kim A, Chang JBP, Kubiak DW, Zhou G, Antin JH, Koreth J, Nikiforow S, Cutler CS, Romee R, Issa NC, Ho VT, Gooptu M, Soiffer RJ, Baden LR
Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. Transplant Cell Ther. 2022 08; 28(8):508.e1-508.e8.
Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome.
Kim HT, Koreth J, Whangbo J, Nikiforow S, Reynolds CG, Stowe P, Ho VT, Cutler C, Antin JH, Soiffer RJ, Ritz J
Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022 08 09; 6(15):4392-4402.
Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther. 2022 10; 28(10):681-693.
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Larocca C, Shanmugam V, Zemmour D, Antin JH, Lane AA
The American Journal of dermatopathology
Shared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient. Am J Dermatopathol. 2022 12 01; 44(12):929-932.
Shared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient.
Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888.
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022 Sep; 9(9):e660-e669.
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
Maurer K, Kim HT, Garrity HM, Liney D, Cutler C, Antin JH, Koreth J, Ritz J, Shapiro RM, Romee R, Ho VT, Gooptu M, Soiffer RJ, Wu CJ, Nikiforow S
Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells. Blood Adv. 2023 06 13; 7(11):2431-2435.
Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells.
Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. J Clin Oncol. 2023 04 20; 41(12):2227-2237.
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Koshy AG, Kim HT, Liegel J, Arnason J, Ho VT, Antin JH, Joyce R, Cutler C, Gooptu M, Nikiforow S, Logan EK, Elavalakanar P, Narcis M, Stroopinsky D, Avigan ZM, Boussi L, Stephenson S, El Banna H, Bindal P, Cheloni G, Avigan DE, Soiffer RJ, Rosenblatt J
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 06 15; 141(24):2932-2943.
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Gupta N, Virgen CA, Goyal A, Lane AA, Antin JH, Divito SJ, Larocca C
Novel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease. JAAD Case Rep. 2023 Mar; 33:67-69.
Novel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease.
Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, Gooptu M, Kelkar AH, Wells SL, Nikiforow S, Koreth J, Romee R, Soiffer RJ, Shapiro RM, Gupta S
Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 07; 29(7):455.e1-455.e9.
Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Shapiro RM, Kim HT, Ansuinelli M, Guleria I, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar A, Ritz J, Wu CJ, Soiffer RJ, Ho VT, Nikiforow S, Romee R
Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023 08 08; 7(15):4080-4088.
Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse.
Long-term health outcomes of allogeneic hematopoietic stem cell transplantation. Front Oncol. 2023; 13:1175794.
Long-term health outcomes of allogeneic hematopoietic stem cell transplantation.
Maurer K, Ho VT, Inyang E, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Nikiforow S, Antin JH, Wu CJ, Ritz J, Soiffer RJ, Kim HT
Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023 08 08; 7(15):3903-3915.
Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
Little JS, Duléry R, Shapiro RM, Aleissa MM, Prockop SE, Koreth J, Ritz J, Antin JH, Cutler C, Nikiforow S, Romee R, Issa NC, Ho VT, Baden LR, Soiffer RJ, Gooptu M
Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplant Cell Ther. 2024 02; 30(2):233.e1-233.e14.
Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft.
Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Contreras ME, Fell G, Letai A, Ritz J, Lindsley RC, Soiffer RJ, Antin JH
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 02 27; 8(4):978-990.
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. Front Immunol. 2024; 15:1328858.
The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.
Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro K, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival. Blood Adv. 2024 09 10; 8(17):4729-4737.
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival.
Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ
Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Transplant Cell Ther. 2024 07; 30(7):687.e1-687.e13.
Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis.
Amonoo HL, Daskalakis E, Wolfe ED, Guo M, Celano CM, Healy BC, Cutler CS, Antin JH, Pirl WF, Park ER, Jim HSL, Lee SJ, LeBlanc TW, El-Jawahri A, Huffman JC
Journal of the National Comprehensive Cancer Network : JNCCN
A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial. J Natl Compr Canc Netw. 2024 06; 22(2 D).
A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial.
Bhatt AS, Freeman SS, Herrera AF, Pedamallu CS, Gevers D, Duke F, Jung J, Michaud M, Walker BJ, Young S, Earl AM, Kostic AD, Ojesina AI, Hasserjian R, Ballen KK, Chen YB, Hobbs G, Antin JH, Soiffer RJ, Baden LR, Garrett WS, Hornick JL, Marty FM, Meyerson M
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 08; 369(6):517-28.
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome.
Richardson PG, Ho VT, Giralt S, Arai S, Mineishi S, Cutler C, Antin JH, Stavitzski N, Niederwieser D, Holler E, Carreras E, Soiffer R
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012 Aug; 3(4):253-65.
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.
Garfall A, Kim HT, Sun L, Ho VT, Armand P, Koreth J, Alyea EP, Soiffer RJ, Antin JH, Ritz J, Cutler C
KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2.
KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.
Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11.
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies SM, Deconinck E, Deeg HJ, Duerst RE, Fasth A, Ghavamzadeh A, Giri N, Goldman FD, Kolb EA, Krance R, Kurtzberg J, Leung WH, Srivastava A, Or R, Richman CM, Rosenberg PS, Toledo Codina JS, Shenoy S, Socié G, Tolar J, Williams KM, Eapen M, Savage SA
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1238-43.
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.
Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM, Kharfan-Dabaja MA, Arai S, Kassim A, Nakamura R, Saldaña BJD, Aljurf M, Hamadani M, Carpenter PA, Antin JH
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024 12; 30(12):1155-1170.
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy.
Eapen M, Antin JH, Tolar J, Arai S, Horwitz ME, Kou J, Leifer E, McCarty JM, Nakamura R, Pulsipher MA, Rowley SD, Horowitz MM, Deeg HJ
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study. EClinicalMedicine. 2024 Oct; 76:102819.
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.
Walters MC, Eapen M, Liu Y, El Rassi F, Waller EK, Levine JE, Strouse JJ, Antin JH, Parikh SH, Bakshi N, Dampier C, Jaroscak JJ, Bergmann S, Wong T, Kota V, Pace B, Lekakis LJ, Lulla P, Nickel RS, Kasow KA, Popat U, Smith W, Yu L, DiFronzo N, Geller N, Kamani N, Klings ES, Hassell K, Mendizabal A, Sullivan K, Neuberg D, Krishnamurti L
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. Blood Adv. 2025 Mar 11; 9(5):955-965.
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
Hickey CL, Zhang MJ, Allbee-Johnson M, Romee R, Majhail NS, Malki MMA, Antin JH, Benjamin CL, Bredeson C, Chhabra S, Grunwald MR, Inamoto Y, Kanakry CG, Milano F, Soiffer RJ, Solomon SR, Spellman SR, Brunstein CG, Cutler C
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2025 Mar; 31(3):174.e1-174.e12.
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Abel GA, Kim HT, Zackon I, Alyea ET, Bailey AS, Winters JP, Meehan KR, Reagan JL, Walsh JH, Walsh TP, Ivanov A, Faggen MA, Sinclair S, Joyce AC, Close SD, Emmert A, Koreth J, Antin JH, Cutler CS, Ho VT, Soiffer RJ
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial. JAMA Oncol. 2025 Mar 01; 11(3):268-275.
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7.
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
Brunner AM, Kim HT, Coughlin E, Alyea EP, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, Pelus LM, Desponts C, Chen YB, Rezner B, Armand P, Koreth J, Glotzbecker B, Ho VT, Alyea E, Isom M, Kao G, Armant M, Silberstein L, Hu P, Soiffer RJ, Scadden DT, Ritz J, Goessling W, North TE, Mendlein J, Ballen K, Zon LI, Antin JH, Shoemaker DD
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81.
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1713-8.
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
Kim HT, Soiffer RJ, Cutler C, Koreth J, Nikiforow S, Shapiro RM, Kelkar A, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Ho VT
Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Haematologica. 2025 Sep 01; 110(9):1998-2008.
Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation.
Issa NC, Marty FM, Leblebjian H, Galar A, Shea MM, Antin JH, Soiffer RJ, Baden LR
Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014 Feb; 20(2):285-7.
Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients.
Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
Li L, Kim HT, Nellore A, Patsoukis N, Petkova V, McDonough S, Politikos I, Nikiforow S, Soiffer R, Antin JH, Ballen K, Cutler C, Ritz J, Boussiotis VA
Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ß-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014 Jan 17; 4:e178.
Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ß-catenin pathway and alters immune reconstitution after UCBT.
Rorije NM, Shea MM, Satyanarayana G, Hammond SP, Ho VT, Baden LR, Antin JH, Soiffer RJ, Marty FM
BK virus disease after allogeneic stem cell transplantation: a cohort analysis. Biol Blood Marrow Transplant. 2014 Apr; 20(4):564-70.
BK virus disease after allogeneic stem cell transplantation: a cohort analysis.
Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, Koreth J, Cutler CS, Ho VT, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Ritz J, Sarantopoulos S
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75.
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
Steroid-refractory acute graft-versus-host disease: is there an effective therapy? Biol Blood Marrow Transplant. 2014 Feb; 20(2):146-8.
Steroid-refractory acute graft-versus-host disease: is there an effective therapy?
Gazourian L, Rogers AJ, Ibanga R, Weinhouse GL, Pinto-Plata V, Ritz J, Soiffer RJ, Antin JH, Washko GR, Baron RM, Ho VT
Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9.
Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Kim HT, Frederick D, Armand P, Andler E, Kao G, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Ho VT
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7.
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05; 123(23):3664-71.
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ
Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8.
Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, MacDonald KP, Hill GR, Blazar BR
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.
Kim HT, Liney DJ, Rizza K, Cutler CS, Koreth J, Nikiforow S, Shapiro RM, Kelkar AH, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ, Ho VT
Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Myelofibrosis. Am J Hematol. 2025 Sep; 100(9):1513-1522.
Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Myelofibrosis.
Little JS, Hebert KM, Neuberg DS, Nikiforow S, Gooptu M, Shapiro RM, Koreth J, Antin JH, Cutler C, Soiffer RJ, Ritz J, Romee R, Ho VT, Issa NC, Baden LR, Duléry R, Prockop SE
Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Jan; 32(1):98.e1-98.e11.
Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation.
Pasvolsky O, Shimony S, Saliba RM, Marcoux C, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin JH, Koreth J, Cutler CS, Paolino JD, Duncan CN, Lehmann LE, DeAngelo DJ, Jain N, Champlin R, Shpall E, Luskin MR, Kebriaei P
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study. Am J Hematol. 2026 Jan; 101(1):16-25.
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study.
Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho V, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl M
Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation. Blood Adv. 2026 Apr 28; 10(8):2817-2828.
Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.
Sariipek NE, Safina KR, Lu WS, Li S, Janes JT, Orden MV, Livak KJ, Heaton H, Ho VT, Koreth J, Luskin MR, Griffin GK, Garcia JS, Lindsley RC, Cutler C, Soiffer RJ, Ritz J, Wu CJ, Antin JH, Lane AA, Gooptu M, van Galen P
bioRxiv : the preprint server for biology
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS. bioRxiv. 2025 Nov 14.
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS.
Armand P, Kim HT, Virtanen JM, Parkkola RK, Itälä-Remes MA, Majhail NS, Burns LJ, DeFor T, Trottier B, Platzbecker U, Antin JH, Wermke M
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1248-51.
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.
Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014 Aug 21; 124(8):1372-7.
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Chang G, Meadows ME, Smallwood JA, Antin JH, Orav EJ
The Journal of neuropsychiatry and clinical neurosciences
Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome. J Neuropsychiatry Clin Neurosci. 2014; 26(3):249-57.
Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome.
Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014 Jul 17; 124(3):334-43.
Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.
Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka K, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.
Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, Ritz J, Alyea EP
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21.
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP, Armand P, Cutler CS, Ho VT, Nikiforow S, Blazar BR, Ritz J, Antin JH, Soiffer RJ, Koreth J
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43.
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
Ion D, Stevenson K, Woo SB, Ho VT, Soiffer R, Antin JH, Treister NS
Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1717-21.
Characterization of oral involvement in acute graft-versus-host disease.
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20; 124(22):3221-7; quiz 3335.
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J, Avigan D, Alyea EP
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, Antin JH, Cutler C, Chen YB
Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014 Dec; 89(12):1097-101.
Outcomes and management strategies for graft failure after umbilical cord blood transplantation.
Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Kim SY, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M, Deeg HJ
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014 Dec; 99(12):1868-75.
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.
Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. 2015 Jan; 21(1):55-9.
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.
Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Ho VT
Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80.
Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Yolin-Raley DS, Dagogo-Jack I, Niell HB, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker BE
The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. J Natl Compr Canc Netw. 2015 Feb; 13(2):184-9.
The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT.
Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B
Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16.
Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival.
Piesche M, Ho VT, Kim H, Nakazaki Y, Nehil M, Yaghi NK, Kolodin D, Weiser J, Altevogt P, Kiefel H, Alyea EP, Antin JH, Cutler C, Koreth J, Canning C, Ritz J, Soiffer RJ, Dranoff G
Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8.
Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.
Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM
Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24.
Blood and marrow transplant clinical trials network state of the Science Symposium 2014.
Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant. 2015 Apr; 21(4):640-5.
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.
Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015 May 01; 21(9):2020-8.
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr; 21(4):761-7.
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Politikos I, Kim HT, Nikiforow S, Li L, Brown J, Antin JH, Cutler C, Ballen K, Ritz J, Boussiotis VA
IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS One. 2015; 10(7):e0132564.
IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults.
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen E
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8.
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ
Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7.
Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation.
Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1776-82.
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.
Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, Armand P, Cutler CS, Ho VT, Glotzbecker B, Nikiforow S, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13.
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep; 2(9):e367-75.
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.
Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen M
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016 Jan 14; 127(2):260-7.
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, Whangbo J, Nikiforow S, Cutler CS, Koreth J, Ho VT, Armand P, Antin JH, Alyea EP, Lacerda JF, Soiffer RJ, Ritz J
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57.
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.
Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol. 2016 Apr; 53(2):98-102.
Cord blood versus haploidentical stem cell transplantation for hematological malignancies.
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65.
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr; 173(1):96-104.
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.
El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, Chen YB
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J, Luckey CJ, Ritz J, Soiffer RJ
Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505.
Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.
Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, Blazar BR, Soiffer RJ, Antin JH, Ritz J
Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97.
Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.
Emerging drugs for graft-versus-host disease. Expert Opin Emerg Drugs. 2016 Jun; 21(2):209-18.
Emerging drugs for graft-versus-host disease.
Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016 05 19; 127(20):2427-38.
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.
Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, Stone RM
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9.
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JH, Auletta J, Komanduri KV, Lindemans C, Riches ML
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 09; 22(9):1636-1645.
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.
McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KP, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, Munn DH, Turka LA, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Blazar BR
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT
Mechanisms, Prevention and Treatment of Chronic Graft-vs.-Host Disease
Cellular and Molecular Studies of Bone Marrow Transplant
Random Trial of CD8 T-Cell Depletion in PBSC Transplantation
NOVEL THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014.
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2016 10; 22(10):1808-1815.
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Nikiforow S, Kim HT, Daley H, Reynolds C, Jones KT, Armand P, Ho VT, Alyea EP, Cutler CS, Ritz J, Antin JH, Soiffer RJ, Koreth J
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jan 01; 16(1):S1.
The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, Armand P
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850.
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.
Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B
Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118.
Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival.
Hirakawa M, Matos TR, Liu H, Koreth J, Kim HT, Paul NE, Murase K, Whangbo J, Alho AC, Nikiforow S, Cutler C, Ho VT, Armand P, Alyea EP, Antin JH, Blazar BR, Lacerda JF, Soiffer RJ, Ritz J
Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.
Politikos I, T Kim H, Karantanos T, Brown J, McDonough S, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Boussiotis VA
Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biol Blood Marrow Transplant. 2017 01; 23(1):103-112.
Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.
Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017 01 12; 129(2):162-170.
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen YB
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2017 09; 178(5):816-819.
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
Nikiforow S, Li S, Snow K, Liney D, Kao GS, Haspel R, Shpall EJ, Glotzbecker B, Sica RA, Armand P, Koreth J, Ho VT, Alyea EP, Ritz J, Soiffer RJ, Antin JH, Dey B, McAfee S, Chen YB, Spitzer T, Avigan D, Cutler CS, Ballen K
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients.
Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK
Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Transplant. 2017 01; 23(1):126-133.
Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.
Ghazal S, Barton S, Boyajian R, Antin JH, Stone RM, Ginsburg ES
Vaginal bleeding in women with leukemia. J Clin Oncol. 2011 May 20; 29(15_suppl):6577.
Vaginal bleeding in women with leukemia.
Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388.
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
Spring LM, Li S, Soiffer R, Antin JH, Alyea E, Glotzbecker B
Readmissions following umbilical cord blood stem cell transplantation. J Clin Oncol. 2014 Oct 20; 32(30_suppl):272.
Readmissions following umbilical cord blood stem cell transplantation.
Yolin-Raley D, Close S, Soiffer R, Antin JH, Jacobson JO, Alyea E
Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients. J Clin Oncol. 2012 Dec; 30(34_suppl):185.
Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients.
Emmert A, Soiffer R, Alyea E, Antin JH, Glotzbecker B
An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation. J Clin Oncol. 2016 Mar; 34(7_suppl):183.
An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation.
Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547.
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197.
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
The Jock and Bunny Adams Chair in Hematology
Woo SB, Allen CM, Orden A, Porter D, Antin JH
Non-gingival soft tissue growths after allogeneic marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1127-32.
Non-gingival soft tissue growths after allogeneic marrow transplantation.
Molrine DC, Guinan EC, Antin JH, Wheeler C, Parsons SK, Weinstein HJ, McGarigle C, Blanding P, Phillips NR, Ciamarra A, George S, Ambrosino DM
Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1149-55.
Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation.
Przepiorka D, Phillips GL, Ratanatharathorn V, Cottler-Fox M, Sehn LH, Antin JH, LeBherz D, Awwad M, Hope J, McClain JB
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998 Dec 01; 92(11):4066-71.
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444-52.
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.
Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002 Nov 15; 100(10):3479-82.
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.
Lee SJ, Loberiza FR, Rizzo JD, Soiffer RJ, Antin JH, Weeks JC
Optimistic expectations and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 Jun; 9(6):389-96.
Optimistic expectations and survival after hematopoietic stem cell transplantation.
Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ
Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83.
Routine screening for psychosocial distress following hematopoietic stem cell transplantation.
Long-term cryopreservation of human stem cells. Bone Marrow Transplant. 1992 Jun; 9(6):487-90.
Long-term cryopreservation of human stem cells.
Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43.
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003 Oct 15; 102(8):2768-76.
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004 Sep 15; 101(6):1478; author reply 1478.
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999; 50:369-86.
The graft-versus-leukemia effects of allogeneic cell therapy.
Rotenstein L, Nathan A, Ghobrial I, Antin J, Parnes A
Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 11; 51(11):1504-1506.
Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation.
Treister N, Li S, Kim H, Lerman M, Sultan A, Alyea EP, Armand P, Cutler C, Ho V, Koreth J, Antin JH, Soiffer R
An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091.
An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.
Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH
Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000; 6(1):35-43.
Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.
Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production. Blood. 2017 05 04; 129(18):2570-2580.
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production.
Porter DL, Collins RH, Hardy C, Kernan NA, Drobyski WR, Giralt S, Flowers ME, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R, Antin JH
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000 Feb 15; 95(4):1214-21.
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
Variable effect of recombinant human granulocyte-macrophage colony-stimulating factor on bone marrow fibrosis in patients with myelodysplasia. Exp Hematol. 1990 May; 18(4):266-70.
Variable effect of recombinant human granulocyte-macrophage colony-stimulating factor on bone marrow fibrosis in patients with myelodysplasia.
Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH
Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1997 Dec 15; 127(12):1080-8.
Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.
Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ
Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999 Feb; 17(2):561-8.
Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Predicting costs of stem-cell transplantation. J Clin Oncol. 2000 Jan; 18(1):64-71.
Predicting costs of stem-cell transplantation.
Relationship Between Intestinal Bacteria and the Anticancer Effect of Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 05 20; 35(15):1636-1637.
Relationship Between Intestinal Bacteria and the Anticancer Effect of Hematopoietic Stem-Cell Transplantation.
Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Shore T, Iacobelli M, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017 Jun; 23(6):997-1004.
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J
Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 05; 102(5):958-966.
Improved survival after acute graft-versus-host disease diagnosis in the modern era.
Wu CJ, Gladwin M, Tisdale J, Hsieh M, Law T, Biernacki M, Rogers S, Wang X, Walters M, Zahrieh D, Antin JH, Ritz J, Krishnamurti L
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7.
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.
Hematology. American Society of Hematology. Education Program
Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. Hematology Am Soc Hematol Educ Program. 2007; 47-54.
Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68.
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P, Atta EH, Ayas M, Boelens JJ, Bonfim C, Deeg HJ, Kapoor N, Lee JW, Nakamura R, Pulsipher MA, Eapen M, Antin JH
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017 07; 102(7):1291-1298.
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia.
Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J
Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 07; 102(7):1185-1191.
Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation.
Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C
Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Prog Clin Biol Res. 1990; 333:207-15.
Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Spiryda LB, Laufer MR, Soiffer RJ, Antin JA
Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003 Dec; 9(12):760-5.
Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment.
Oh H, Loberiza FR, Zhang MJ, Ringdén O, Akiyama H, Asai T, Miyawaki S, Okamoto S, Horowitz MM, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb HJ, Litzow MR, McCarthy PL, Neudorf SM, Serna DS, Socié G, Tiberghien P, Barrett AJ
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005 Feb 15; 105(4):1408-16.
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11.
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
Wen PY, Blanchard KL, Block CC, Loeffler JS, Davis DG, Lacroix LA, Antin JH
Development of Lhermitte's sign after bone marrow transplantation. Cancer. 1992 May 01; 69(9):2262-6.
Development of Lhermitte's sign after bone marrow transplantation.
Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF, Mattes-Ritz A, Alyea EP, Antin JH, Soiffer RJ, Ritz J
A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9.
A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation.
Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004 Sep 01; 104(5):1559-64.
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, Antin JH
Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006 Aug; 38(4):305-10.
Quality of life associated with acute and chronic graft-versus-host disease.
Molrine DC, Antin JH, Guinan EC, Soiffer RJ, MacDonald K, Malley R, Malinoski F, Trocciola S, Wilson M, Ambrosino DM
Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6.
Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.
Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
Ziegler TR, Bye RL, Persinger RL, Young LS, Antin JH, Wilmore DW
The American journal of the medical sciences
Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: a pilot study. Am J Med Sci. 1998 Jan; 315(1):4-10.
Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: a pilot study.
Ho VT, Kim HT, Li S, Hochberg EP, Cutler C, Lee SJ, Fisher DC, Milford E, Kao G, Daley H, Levin J, Ng A, Mauch P, Alyea EP, Antin JH, Soiffer RJ
Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004 Dec; 34(11):987-94.
Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease.
Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May; 11(5):383-8.
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W, Antin JH, Ritz J
Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45.
Evidence for ineffective erythropoiesis in severe sickle cell disease.
Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, Nademanee A, Noreen H, King R, Confer D, Kernan NA
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000 Dec 15; 96(13):4096-102.
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program.
Boswell GW, Bekersky I, Fay J, Wingard J, Antin J, Weisdorf D, Maher R, Fitzsimmons W, Nash R
Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant. 1998 Jan; 21(1):23-8.
Tacrolimus pharmacokinetics in BMT patients.
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44.
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
Lee SJ, Anasetti C, Horowitz MM, Antin JH
Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol. 1998 Sep; 16(9):2897-903.
Initial therapy for chronic myelogenous leukemia: playing the odds.
Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, Morrow FD, Jacobs DO, Smith RJ, Antin JH
Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med. 1992 May 15; 116(10):821-8.
Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study.
Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 01; 109(7):3108-14.
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ
Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 Aug; 40(3):209-17.
Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy.
Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1268-85.
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.
Benjamin RJ, Linsley L, Fountain D, Churchill WH, Sieff C, Cannon ME, Uhl L, Gaynes L, Antin JH, Wheeler C
Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield. Transfusion. 1997 Jan; 37(1):79-85.
Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield.
Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH
Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997 Nov; 20(9):737-43.
Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.
McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ
Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000 Apr 01; 95(7):2219-25.
Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program.
Schiff D, O'Neill B, Wijdicks E, Antin JH, Wen PY
Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001 Oct 23; 57(8):1486-8.
Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation?
A 41-year-old woman with chronic myelogenous leukemia. JAMA. 2003 Aug 27; 290(8):1083-90.
A 41-year-old woman with chronic myelogenous leukemia.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62.
Rituximab for steroid-refractory chronic graft-versus-host disease.
Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JL, Antin JH
Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996 Nov; 18(5):975-80.
Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. Cancer Treat Res. 1997; 77:57-85.
Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions.
Chan CY, Molrine DC, Antin JH, Wheeler C, Guinan EC, Weinstein HJ, Phillips NR, McGarigle C, Harvey S, Schnipper C, Ambrosino DM
Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 1997 Jul; 20(1):33-8.
Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT).
Lee SJ, Fairclough D, Antin JH, Weeks JC
Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA. 2001 Feb 28; 285(8):1034-8.
Discrepancies between patient and physician estimates for the success of stem cell transplantation.
Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA
A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Jul; 28(2):187-96.
A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002 Mar 15; 99(6):1971-7.
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.
Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003 Aug 01; 102(3):802-9.
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.
Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106.
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Andrykowski MA, Carpenter JS, Greiner CB, Altmaier EM, Burish TG, Antin JH, Gingrich R, Cordova MJ, Henslee-Downey PJ
Energy level and sleep quality following bone marrow transplantation. Bone Marrow Transplant. 1997 Oct; 20(8):669-79.
Energy level and sleep quality following bone marrow transplantation.
Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8.
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5.
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
Antin JH, Emmert-Buck MR, Aplin AE, Cheng SY, Cryns VL, Wang D
Launching of American Journal of Cancer Research. Am J Cancer Res. 2011; 1(1):i.
Launching of American Journal of Cancer Research.
Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, Cutler CS, Koreth J, Armand P, Ho VT, Antin JH, Soiffer RJ, Baden LR
Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Mar; 17(3):434-8.
Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
T-cell depletion in GVHD: less is more? Blood. 2011 Jun 09; 117(23):6061-2.
Roth MS, Antin JH, Bingham EL, Ginsburg D
Use of polymerase chain reaction-detected sequence polymorphisms to document engraftment following allogeneic bone marrow transplantation. Transplantation. 1990 Apr; 49(4):714-20.
Use of polymerase chain reaction-detected sequence polymorphisms to document engraftment following allogeneic bone marrow transplantation.
Lee SJ, Churchill WH, Konugres A, Gilliland DG, Antin JH
Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation--treatment with anti-D immunoglobulin. Bone Marrow Transplant. 1997 Jan; 19(2):173-4.
Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation--treatment with anti-D immunoglobulin.
Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC
The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998 Dec 01; 92(11):4047-52.
The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia.
Best practice & research. Clinical haematology
Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol. 2006; 19(4):737-55.
Donor leukocyte infusions in myeloid malignancies: new strategies.
Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A
Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402. Bone Marrow Transplant. 2017 Sep; 52(9):1300-1303.
Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.
Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, de Lima M, Gore SD, Potts RG, Silverman LR, Jones RB, McCarthy PL, Hahn T
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009 Feb; 15(2):137-72.
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
Gibson CJ, Kennedy JA, Nikiforow S, Kuo FC, Alyea EP, Ho V, Ritz J, Soiffer R, Antin JH, Lindsley RC
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94.
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul 15; 104(2):579-85.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR
An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15; 2(12).
An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.
Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH
Treatment of chronic graft-versus-host disease with clofazimine. Blood. 1997 Apr 01; 89(7):2298-302.
Treatment of chronic graft-versus-host disease with clofazimine.
Treister NS, Cook EF, Antin J, Lee SJ, Soiffer R, Woo SB
Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Jan; 14(1):110-5.
Clinical evaluation of oral chronic graft-versus-host disease.
Porter DL, Collins RH, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH
Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999; 5(4):253-61.
Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.
Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992 Dec 15; 80(12):2964-8.
Cytokine dysregulation and acute graft-versus-host disease.
Porter DL, Connors JM, Van Deerlin VM, Duffy KM, McGarigle C, Saidman SL, Leonard DG, Antin JH
Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999 Apr; 17(4):1234.
Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.
Peripheral blood neutrophils in chronically neutropenic patients respond to granulocyte-macrophage colony-stimulating factor with a specific increase in CR1 expression and CR1 transcription. Blood. 1992 Apr 01; 79(7):1667-71.
Peripheral blood neutrophils in chronically neutropenic patients respond to granulocyte-macrophage colony-stimulating factor with a specific increase in CR1 expression and CR1 transcription.
Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001; 7(9):473-85.
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.
McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer B, Warren EH, Zhang B, Zhao LP, Ginsburg D, Soiffer RJ, Partanen J, Hansen JA, Ritz J, Palotie A, Altshuler D
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009 Dec; 41(12):1341-4.
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.
Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017 07; 178(1):112-118.
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009 Mar 26; 113(13):3110-8.
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
DeMarinis V, Barsky AJ, Antin JH, Chang G
Health psychology and distress after haematopoietic stem cell transplantation. Eur J Cancer Care (Engl). 2009 Jan; 18(1):57-63.
Health psychology and distress after haematopoietic stem cell transplantation.
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P, Koreth J, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204.
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
Stem cell transplantation-harnessing of graft-versus-malignancy. Curr Opin Hematol. 2003 Nov; 10(6):440-4.
Stem cell transplantation-harnessing of graft-versus-malignancy.
Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10(5):328-36.
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D
Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004 Oct; 10(10):655-68.
Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease.
Ginsburg D, Antin JH, Smith BR, Orkin SH, Rappeport JM
Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms. J Clin Invest. 1985 Feb; 75(2):596-603.
Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms.
Andrykowski MA, Brady MJ, Greiner CB, Altmaier EM, Burish TG, Antin JH, Gingrich R, McGarigle C, Henslee-Downey PJ
'Returning to normal' following bone marrow transplantation: outcomes, expectations and informed consent. Bone Marrow Transplant. 1995 Apr; 15(4):573-81.
'Returning to normal' following bone marrow transplantation: outcomes, expectations and informed consent.
Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994 Aug 15; 84(4):1342-8.
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
Immune reconstitution: the major barrier to successful stem cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2 Suppl 2):43-5.
Immune reconstitution: the major barrier to successful stem cell transplantation.
Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005 May 19; 5:7.
Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report.
Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Bunn HF
Erythropoietin gene regulation: from the laboratory to the bedside. Contrib Nephrol. 1991; 88:35-45; discussion 46-7.
Erythropoietin gene regulation: from the laboratory to the bedside.
Mental status changes after hematopoietic stem cell transplantation. Cancer. 2009 Oct 01; 115(19):4625-35.
Mental status changes after hematopoietic stem cell transplantation.
Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH
Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, Antin JH
Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol. 1995 Sep; 165(3):627-31.
Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases.
Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C
Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998 Jan 15; 91(2):717-23.
Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation.
Vance E, George S, Guinan EC, Wheeler C, Antin JH, Ambrosino DM, Molrine DC
Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant. 1998 Oct; 22(8):735-41.
Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation.
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50.
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica. 2010 Mar; 95(3):364-6.
Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation.
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH
Annals of oncology : official journal of the European Society for Medical Oncology
A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-1613.
A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.
Blaser BW, Kim HT, Alyea EP, Ho VT, Cutler C, Armand P, Koreth J, Antin JH, Plutzky J, Soiffer RJ
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83.
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.
Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, Koreth J, Ho V, Alyea E, Ballen K, Ritz J, Soiffer RJ, Milford E, Antin JH
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7.
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43.
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Sultan AS, Zimering Y, Petruzziello G, Alyea EP, Antin JH, Soiffer RJ, Ho VT, Sonis ST, Woo SB, Marty FM, Treister NS
Oral surgery, oral medicine, oral pathology and oral radiology
Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep; 124(3):253-260.
Oral Surg Oral Med Oral Pathol Oral Radiol
Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation.
Ofran Y, Kim HT, Brusic V, Blake L, Mandrell M, Wu CJ, Sarantopoulos S, Bellucci R, Keskin DB, Soiffer RJ, Antin JH, Ritz J
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium
Acute leukemias, myelodysplasia, and lymphomas. Clin Geriatr Med. 1985 Nov; 1(4):795-826.
Acute leukemias, myelodysplasia, and lymphomas.
Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8.
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.
Chen YB, Aldridge J, Kim HT, Ballen KK, Cutler C, Kao G, Liney D, Bourdeau G, Alyea EP, Armand P, Koreth J, Ritz J, Spitzer TR, Soiffer RJ, Antin JH, Ho VT
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12.
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, Ho V, Lee SJ, Soiffer R, Antin JH
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Jul; 11(7):551-7.
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Chang G, McGarigle C, Spitzer TR, McAfee SL, Harris F, Piercy K, Goetz MN, Antin JH
A comparison of related and unrelated marrow donors. Psychosom Med. 1998 Mar-Apr; 60(2):163-7.
A comparison of related and unrelated marrow donors.
Benjamin RJ, Connors JM, McGurk S, Churchill WH, Antin JH
Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 1998; 4(3):151-6.
Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia.
Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, Ferrara JL
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(5):373-7.
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation.
DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH
Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002 Dec 15; 100(13):4367-71.
Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation.
Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics. 2004 Sep-Oct; 45(5):378-85.
Predictors of 1-year survival assessed at the time of bone marrow transplantation.
Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991 Jul; 9(7):1215-23.
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, Antin JH
Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):552-9.
Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA, Jarolim P
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71.
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.
Bone marrow progenitor cells induce a regulatory autologous proliferative T lymphocyte response. J Immunol. 1989 Feb 01; 142(3):766-72.
Bone marrow progenitor cells induce a regulatory autologous proliferative T lymphocyte response.
Mawardi H, Elad S, Correa ME, Stevenson K, Woo SB, Almazrooa S, Haddad R, Antin JH, Soiffer R, Treister N
Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91.
Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes.
Mitus AJ, Stein R, Rappeport JM, Antin JH, Weinstein HJ, Alper CA, Smith BR
Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood. 1989 Dec; 74(8):2764-8.
Monoclonal and oligoclonal gammopathy after bone marrow transplantation.
Chang G, Antin JH, Orav EJ, Randall U, McGarigle C, Behr HM
Substance abuse and bone marrow transplant. Am J Drug Alcohol Abuse. 1997 May; 23(2):301-8.
Substance abuse and bone marrow transplant.
Lee SJ, Fairclough D, Parsons SK, Soiffer RJ, Fisher DC, Schlossman RL, Antin JH, Weeks JC
Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol. 2001 Jan 01; 19(1):242-52.
Recovery after stem-cell transplantation for hematologic diseases.
Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ, LeMaistre CF, Litzow MR, Marks D, Waller EK, Matlack M, Giralt S, Horowitz MM
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001 Dec 01; 98(12):3205-11.
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase.
Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma. 2001 Feb; 40(5-6):499-509.
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9.
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.
Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6.
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Chang G, Orav EJ, McNamara T, Tong MY, Antin JH
Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome. Cancer. 2004 Aug 15; 101(4):782-9.
Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome.
Scheltinga MR, Young LS, Benfell K, Bye RL, Ziegler TR, Santos AA, Antin JH, Schloerb PR, Wilmore DW
Glutamine-enriched intravenous feedings attenuate extracellular fluid expansion after a standard stress. Ann Surg. 1991 Oct; 214(4):385-93; discussion 393-5.
Glutamine-enriched intravenous feedings attenuate extracellular fluid expansion after a standard stress.
Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64.
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706.
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.
Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR
Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007 Jul; 13(7):838-43.
Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, Antin JH, Ritz J
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15; 13(20):6107-14.
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002 Jul 04; 347(1):36-42.
Clinical practice. Long-term care after hematopoietic-cell transplantation in adults.
Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.
Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J, Alyea EP, Antin JH, Soiffer RJ
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35.
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG
Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402. Bone Marrow Transplant. 2018 01; 53(1):64-68.
Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.
The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. Curr Hematol Malig Rep. 2006 Sep; 1(3):160-7.
The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
Armistead PM, Mohseni M, Gerwin R, Walsh EC, Iravani M, Chahardouli B, Rostami S, Zhang W, Neuberg D, Rioux J, Ghavamzadeh A, Ritz J, Antin JH, Wu CJ
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
Abou-Nassar KE, Kim HT, Blossom J, Ho VT, Soiffer RJ, Cutler CS, Alyea EP, Koreth J, Antin JH, Armand P
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):708-15.
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.
Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55.
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.
Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, Koreth J, Alyea EP, Neufeld EJ, Kwong RY, Soiffer RJ, Antin JH
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7.
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.
Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8.
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Bierer BE, Emerson SG, Antin J, Maziarz R, Rappeport JM, Smith BR, Burakoff SJ
Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation. Transplantation. 1988 Dec; 46(6):835-9.
Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation.
Ho VT, Kim HT, Liney D, Milford E, Gribben J, Cutler C, Lee SJ, Antin JH, Soiffer RJ, Alyea EP
HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May; 37(9):845-50.
HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.
McGrail LH, Sehn LH, Weiss RB, Robson MR, Antin JH, Byrd JC
Pancreatitis during therapy of acute myeloid leukemia: cytarabine related? Ann Oncol. 1999 Nov; 10(11):1373-6.
Pancreatitis during therapy of acute myeloid leukemia: cytarabine related?
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000 Sep 15; 96(6):2062-8.
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
Acute graft-versus-host disease: inflammation run amok? J Clin Invest. 2001 Jun; 107(12):1497-8.
Acute graft-versus-host disease: inflammation run amok?
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb; 14(2):197-207.
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.
Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J
Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899.
Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.
Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002 Jul 15; 100(2):406-14.
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E
Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991 Oct 15; 78(8):2139-49.
Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.
Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011 Mar; 17(3):291-9.
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.
Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005 Mar; 11(3):261-2.
Contribution of bone marrow-derived endothelial cells to human tumor vasculature.
Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520.
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72.
Does iron overload really matter in stem cell transplantation?
Antin JH, Smith BR, Holmes W, Rosenthal DS
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood. 1988 Aug; 72(2):705-13.
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome.
Antin JH, Smith BR, Ewenstein BM, Arceci RJ, Lipton JM, Page PL, Rappeport JM
HTLV-III infection after bone marrow transplantation. Blood. 1986 Jan; 67(1):160-3.
HTLV-III infection after bone marrow transplantation.
Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013 Jun 15; 207(12):1888-97.
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008 Feb; 14(2):187-96.
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
Biology and management of acute graft-versus-host disease. Cancer Treat Res. 2009; 144:257-75.
Biology and management of acute graft-versus-host disease.
Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1475-8.
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93.
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS, LaCasce AS, Jacobsen ED, Fisher DC, Soiffer RJ, Alyea EP, Koreth J, Freedman AS
(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9.
(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
Herrera AF, Soriano G, Bellizzi AM, Hornick JL, Ho VT, Ballen KK, Baden LR, Cutler CS, Antin JH, Soiffer RJ, Marty FM
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011 Sep 01; 365(9):815-24.
Cord colitis syndrome in cord-blood stem-cell transplantation.
Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug; 14(8):920-6.
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Yanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH, Whitfield J, Custer J, Jones D, Ferrara JL, Cooke KR
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008 Oct 15; 112(8):3073-81.
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, Ho VT, Alyea EP, Koreth J, Blazar BR, Soiffer RJ, Antin JH, Ritz J
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74.
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, Spitzer TR, Soiffer R, Antin JH, Ritz J
Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1066-76.
Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.
Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9.
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
Koreth J, Aldridge J, Kim HT, Alyea EP, Cutler C, Armand P, Ritz J, Antin JH, Soiffer RJ, Ho VT
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800.
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Curr Opin Hematol. 2010 Nov; 17(6):500-4.
Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30.
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012 Jan 05; 119(1):296-307.
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1446-54.
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul; 18(7):1007-11.
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279.
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. Blood Adv. 2017 Mar 28; 1(9):573-576.
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.
DeFilipp Z, Nazarian RM, El-Jawahri A, Li S, Brown J, Del Rio C, Smith M, Valles B, Ballen KK, McAfee SL, Rosenblatt J, Antin JH, Cutler CS, Chen YB
Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2017 Oct 10; 1(22):1919-1922.
Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease.
Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13; 330(2):100-6.
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.
Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 06; 24(6):1274-1280.
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.
Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood. 1989 Aug 01; 74(2):882-5.
Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia.
Richardson PG, Ho VT, Cutler C, Glotzbecker B, Antin JH, Soiffer R
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90.
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.
Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappeport JM, Keohan ML, Martin P, Smith BR
Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med. 1985 Jun 01; 161(6):1483-502.
Phenotype of recovering lymphoid cell populations after marrow transplantation.
Antin J, Gibbs J, Holt J, Young RC, Smith GP
Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J Comp Physiol Psychol. 1975 Sep; 89(7):784-90.
Cholecystokinin elicits the complete behavioral sequence of satiety in rats.
Stroncek DF, Holland PV, Bartch G, Bixby T, Simmons RG, Antin JH, Anderson KC, Ash RC, Bolwell BJ, Hansen JA
Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993 Apr 01; 81(7):1940-6.
Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program.
Nichols WC, Antin JH, Lunetta KL, Terry VH, Hertel CE, Wheatley MA, Arnold ND, Siemieniak DR, Boehnke M, Ginsburg D
Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood. 1996 Dec 15; 88(12):4429-34.
Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease.
Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997 Feb; 15(2):433-44.
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998 Feb; 12(1):123-50.
Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia.
Ballen KK, Donadio D, Bouloux C, McCarthy P, Weinstein H, Antin JH
Herpes simplex virus and neutropenia following bone marrow transplantation. Transplantation. 1992 Sep; 54(3):553-5.
Herpes simplex virus and neutropenia following bone marrow transplantation.
Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V, Weisdorf D, Confer DL
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001 Oct 01; 98(7):2043-51.
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.
Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, Ginsburg D
Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood. 1992 Jan 01; 79(1):276-82.
Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia.
Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004 Sep; 34(6):471-6.
Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation.
Fountain D, Ralston M, Higgins N, Gorlin JB, Uhl L, Wheeler C, Antin JH, Churchill WH, Benjamin RJ
Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion. 1997 Jun; 37(6):585-91.
Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components.
Kraus MD, Shahsafaei A, Antin J, Odze RD
Relationship of Bcl-2 expression with apoptosis and proliferation in colonic graft versus host disease. Hum Pathol. 1998 Aug; 29(8):869-75.
Relationship of Bcl-2 expression with apoptosis and proliferation in colonic graft versus host disease.
Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Socié G
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005 Aug 15; 106(4):1495-500.
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.
Donor leukocyte infusions and graft-versus-malignancy. J Clin Apher. 2005 Jul; 20(2):113-6.
Donor leukocyte infusions and graft-versus-malignancy.
Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, Weinstock DM
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71.
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia.
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998 Oct 01; 92(7):2303-14.
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J
CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.
Loberiza FR, Rizzo JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, Lee SJ
Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002 Apr 15; 20(8):2118-26.
Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases.
Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ
Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 2002 Jul 15; 74(1):49-54.
Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Milinkovic M, Antin JH, Hergrueter CA, Underhill CB, Sackstein R
CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood. 2004 Jan 15; 103(2):740-2.
CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD.
Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH
Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4.
Guillain-Barré syndrome following allogeneic bone marrow transplantation.
Kraus MD, Feran-Doza M, Garcia-Moliner ML, Antin J, Odze RD
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Cytomegalovirus infection in the colon of bone marrow transplantation patients. Mod Pathol. 1998 Jan; 11(1):29-36.
Cytomegalovirus infection in the colon of bone marrow transplantation patients.